BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Renal Cell Carcinoma readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Renal Cell Carcinoma\
 , from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05319015-1973@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05319015)
DESCRIPTION:Pembrolizumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Neoadju
 vant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus\nEstimated primar
 y completion: December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05319015
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05263050-1974@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05263050)
DESCRIPTION:Nivolumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Trial of an
  Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcino
 ma and Neuroendocrine Tumors\nEstimated primary completion: December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05263050
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05263050-2031@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT05263050)
DESCRIPTION:Cabozantinib\, phase 2\, Renal Cell Carcinoma.\nStudy: Trial of
  an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carc
 inoma and Neuroendocrine Tumors\nEstimated primary completion: December 20
 26. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/cabozantinib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05263050
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05678673-1974@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Nivolumab: Phase 3 readout est. (NCT05678673)
DESCRIPTION:Nivolumab\, phase 3\, Renal Cell Carcinoma.\nStudy: Study of XL
 092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-C
 lear Cell Renal Cell Carcinoma\nEstimated primary completion: 15 December 
 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05678673
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05678673-2819@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Zanzalintinib: Phase 3 readout est. (NCT05678673)
DESCRIPTION:Zanzalintinib\, phase 3\, Renal Cell Carcinoma.\nStudy: Study o
 f XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic N
 on-Clear Cell Renal Cell Carcinoma\nEstimated primary completion: 15 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zanzalintin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5678673
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04413123-1974@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20261220
DTEND;VALUE=DATE:20261221
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04413123)
DESCRIPTION:Nivolumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Cabozantini
 b In Combo With NIVO + IPI In Advanced NCCRCC\nEstimated primary completio
 n: 20 December 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04413123
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04413123-2009@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20261220
DTEND;VALUE=DATE:20261221
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT04413123)
DESCRIPTION:Ipilimumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Cabozantin
 ib In Combo With NIVO + IPI In Advanced NCCRCC\nEstimated primary completi
 on: 20 December 2026. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /ipilimumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT04413123
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04413123-2031@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20261220
DTEND;VALUE=DATE:20261221
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT04413123)
DESCRIPTION:Cabozantinib\, phase 2\, Renal Cell Carcinoma.\nStudy: Cabozant
 inib In Combo With NIVO + IPI In Advanced NCCRCC\nEstimated primary comple
 tion: 20 December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/cabozantinib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04413123
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05468697-11244@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20261222
DTEND;VALUE=DATE:20261223
SUMMARY:Welireg (Belzutifan): Phase 1/2 readout est. (NCT05468697)
DESCRIPTION:Welireg (Belzutifan)\, phase 1/2\, Renal Cell Carcinoma.\nStudy
 : A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus B
 elzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (
 MK-6482-024/LITESPARK-024)\nEstimated primary completion: 22 December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/belzutifan#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05468697
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05768464-2214@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Axitinib: Phase 2 readout est. (NCT05768464)
DESCRIPTION:Axitinib\, phase 2\, Renal Cell Carcinoma.\nStudy: Postoperativ
 e Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recur
 rence Factors\nEstimated primary completion: 30 December 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/axitinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05768464
URL:https://assetmemo.bio/drug/axitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04140526-1973@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04140526)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Safety\, PK and Efficacy of ONC-392 in Monotherapy and in Combination of 
 Anti-PD-1 in Advanced Solid Tumors and NSCLC\nEstimated primary completion
 : 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 embrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT04140526
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06835972-2031@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Cabozantinib: Phase 1/2 readout est. (NCT06835972)
DESCRIPTION:Cabozantinib\, phase 1/2\, Clear Cell Renal Cell Carcinoma.\nSt
 udy: A Study of Abemaciclib and Cabozantinib in People With Clear Cell Ren
 al Cell Carcinoma (ccRCC)\nEstimated primary completion: February 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/cabozantinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06835972
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01684397-1918@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270220
DTEND;VALUE=DATE:20270221
SUMMARY:Votrient (Pazopanib): Phase 1/2 readout est. (NCT01684397)
DESCRIPTION:Votrient (Pazopanib)\, phase 1/2\, Renal Cell Carcinoma.\nStudy
 : Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previo
 usly Untreated Metastatic Kidney Cancer\nEstimated primary completion: 20 
 February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pazopa
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 01684397
URL:https://assetmemo.bio/drug/pazopanib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01684397-2008@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270220
DTEND;VALUE=DATE:20270221
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT01684397)
DESCRIPTION:Bevacizumab\, phase 1/2\, Renal Cell Carcinoma.\nStudy: Pazopan
 ib Hydrochloride and Bevacizumab in Treating Patients With Previously Untr
 eated Metastatic Kidney Cancer\nEstimated primary completion: 20 February 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0168439
 7
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07159191-2214@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270220
DTEND;VALUE=DATE:20270221
SUMMARY:Axitinib: Phase 2 readout est. (NCT07159191)
DESCRIPTION:Axitinib\, phase 2\, Renal Cell Carcinoma.\nStudy: Envafolimab 
 Combined With Axitinib as First-Line Treatment for Patients With Advanced 
 Renal Cell Carcinoma\nEstimated primary completion: 20 February 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/axitinib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07159191
URL:https://assetmemo.bio/drug/axitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03634540-2031@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT03634540)
DESCRIPTION:Cabozantinib\, phase 2\, Clear Cell Renal Cell Carcinoma.\nStud
 y: A Trial of Belzutifan (PT2977\, MK-6482) in Combination With Cabozantin
 ib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)\
 nEstimated primary completion: 26 February 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/cabozantinib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT03634540
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03634540-11244@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Welireg (Belzutifan): Phase 2 readout est. (NCT03634540)
DESCRIPTION:Welireg (Belzutifan)\, phase 2\, Renal Cell Carcinoma.\nStudy: 
 A Trial of Belzutifan (PT2977\, MK-6482) in Combination With Cabozantinib 
 in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)\nEs
 timated primary completion: 26 February 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/belzutifan#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT03634540
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047379-1973@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06047379)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant\, G
 lioblastoma IDH-wildtype or Brain Metastasis\nEstimated primary completion
 : 28 February 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 embrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06047379
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047379-1974@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT06047379)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Saf
 ety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant\, Gliob
 lastoma IDH-wildtype or Brain Metastasis\nEstimated primary completion: 28
  February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivol
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06047379
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047379-2008@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06047379)
DESCRIPTION:Bevacizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: S
 afety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant\, Gli
 oblastoma IDH-wildtype or Brain Metastasis\nEstimated primary completion: 
 28 February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bev
 acizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06047379
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047379-2009@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT06047379)
DESCRIPTION:Ipilimumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Sa
 fety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant\, Glio
 blastoma IDH-wildtype or Brain Metastasis\nEstimated primary completion: 2
 8 February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipil
 imumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06047379
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03866382-1974@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03866382)
DESCRIPTION:Nivolumab\, phase 2\, Urothelial Carcinoma.\nStudy: Testing the
  Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With 
 One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
 \nEstimated primary completion: 28 February 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT03866382
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03866382-2009@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT03866382)
DESCRIPTION:Ipilimumab\, phase 2\, Urothelial Carcinoma.\nStudy: Testing th
 e Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With
  One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumor
 s\nEstimated primary completion: 28 February 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT03866382
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03866382-2031@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT03866382)
DESCRIPTION:Cabozantinib\, phase 2\, Renal Cell Carcinoma.\nStudy: Testing 
 the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) Wi
 th One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tum
 ors\nEstimated primary completion: 28 February 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/cabozantinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT03866382
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05239533-1974@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05239533)
DESCRIPTION:Nivolumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Study of Ni
 volumab in Combination With 177Lu-girentuximab for Kidney Cancer\nEstimate
 d primary completion: March 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05239533
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03873402-1974@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270311
DTEND;VALUE=DATE:20270312
SUMMARY:Nivolumab: Phase 3 readout est. (NCT03873402)
DESCRIPTION:Nivolumab\, phase 3\, Renal Cell Carcinoma.\nStudy: A Study of 
 Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants 
 With Advanced Kidney Cancer\nEstimated primary completion: 11 March 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT03873402
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03873402-2009@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270311
DTEND;VALUE=DATE:20270312
SUMMARY:Ipilimumab: Phase 3 readout est. (NCT03873402)
DESCRIPTION:Ipilimumab\, phase 3\, Renal Cell Carcinoma.\nStudy: A Study of
  Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants
  With Advanced Kidney Cancer\nEstimated primary completion: 11 March 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT03873402
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03401788-11244@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270429
DTEND;VALUE=DATE:20270430
SUMMARY:Welireg (Belzutifan): Phase 2 readout est. (NCT03401788)
DESCRIPTION:Welireg (Belzutifan)\, phase 2\, Renal Cell Carcinoma.\nStudy: 
 A Phase 2 Study of Belzutifan (PT2977\, MK-6482) for the Treatment of Von 
 Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482
 -004)\nEstimated primary completion: 29 April 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/belzutifan#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT03401788
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04322955-1974@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04322955)
DESCRIPTION:Nivolumab\, phase 2\, Renal Cell Carcinoma.\nStudy: CYTO Reduct
 ive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibi
 tion\nEstimated primary completion: May 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04322955
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04322955-2031@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT04322955)
DESCRIPTION:Cabozantinib\, phase 2\, Renal Cell Carcinoma.\nStudy: CYTO Red
 uctive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inh
 ibition\nEstimated primary completion: May 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/cabozantinib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04322955
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06265285-1974@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06265285)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Compa
 rison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab
  Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls 
 (CCBW) Program\nEstimated primary completion: 1 May 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06265285
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06638931-1974@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06638931)
DESCRIPTION:Nivolumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Agnostic Th
 erapy in Rare Solid Tumors\nEstimated primary completion: July 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06638931
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07187778-1973@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270719
DTEND;VALUE=DATE:20270720
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07187778)
DESCRIPTION:Pembrolizumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Phase I
 I Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as 
 Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)\nEstimated 
 primary completion: 19 July 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07187778
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07187778-11244@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270719
DTEND;VALUE=DATE:20270720
SUMMARY:Welireg (Belzutifan): Phase 2 readout est. (NCT07187778)
DESCRIPTION:Welireg (Belzutifan)\, phase 2\, Renal Cell Carcinoma.\nStudy: 
 Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combinat
 ion as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)\nEst
 imated primary completion: 19 July 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/belzutifan#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07187778
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03541902-2031@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT03541902)
DESCRIPTION:Cabozantinib\, phase 2\, Renal Cell Carcinoma.\nStudy: Cabozant
 inib or Sunitinib Malate in Treating Participants With Metastatic Variant 
 Histology Renal Cell Carcinoma\nEstimated primary completion: 31 July 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/cabozantinib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT03541902
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03635892-1974@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03635892)
DESCRIPTION:Nivolumab\, phase 2\, Renal Cell Carcinoma.\nStudy: A Study of 
 Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell
  Renal Cell Carcinoma\nEstimated primary completion: August 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT03635892
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03635892-2031@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT03635892)
DESCRIPTION:Cabozantinib\, phase 2\, Renal Cell Carcinoma.\nStudy: A Study 
 of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear C
 ell Renal Cell Carcinoma\nEstimated primary completion: August 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/cabozantinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT03635892
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07937553-9023@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Everolimus: Phase 2 readout est. (NCT07937553)
DESCRIPTION:Everolimus\, phase 2\, Renal Cell Carcinoma.\nStudy: Combinatio
 ns With Lenvatinib in Patients With Metastatic Chromophobe Renal Cell Carc
 inoma.\nEstimated primary completion: 1 August 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/everolimus#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07937553
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05931393-2031@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT05931393)
DESCRIPTION:Cabozantinib\, phase 2\, Renal Cell Carcinoma.\nStudy: Sequenti
 al Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)\nEsti
 mated primary completion: 1 September 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/cabozantinib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05931393
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07077161-2031@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT07077161)
DESCRIPTION:Cabozantinib\, phase 2\, Renal Cell Carcinoma.\nStudy: Cabozant
 inib Dose Skipping as an Alternative to Dose Reductions\nEstimated primary
  completion: 1 September 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/cabozantinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07077161
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05361720-1974@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05361720)
DESCRIPTION:Nivolumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Genetic Tes
 ting to Select Therapy for the Treatment of Advanced or Metastatic Kidney 
 Cancer\, OPTIC RCC Study\nEstimated primary completion: 1 October 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05361720
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05361720-2009@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT05361720)
DESCRIPTION:Ipilimumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Genetic Te
 sting to Select Therapy for the Treatment of Advanced or Metastatic Kidney
  Cancer\, OPTIC RCC Study\nEstimated primary completion: 1 October 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05361720
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05361720-2031@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT05361720)
DESCRIPTION:Cabozantinib\, phase 2\, Clear Cell Renal Cell Carcinoma.\nStud
 y: Genetic Testing to Select Therapy for the Treatment of Advanced or Meta
 static Kidney Cancer\, OPTIC RCC Study\nEstimated primary completion: 1 Oc
 tober 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cabozanti
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05361720
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07123090-2214@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Axitinib: Phase 2 readout est. (NCT07123090)
DESCRIPTION:Axitinib\, phase 2\, Renal Cell Carcinoma.\nStudy: A Study of S
 asanlimab\, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma\nE
 stimated primary completion: 1 October 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/axitinib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07123090
URL:https://assetmemo.bio/drug/axitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05831891-2237@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20271022
DTEND;VALUE=DATE:20271023
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0583189
 1)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Renal Cell Carcin
 oma.\nStudy: Fruquintinib Plus Serplulimab as First-Line Therapy for Metas
 tatic Non-Clear Cell Renal Cell Carcinoma\nEstimated primary completion: 2
 2 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fruqu
 intinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05831891
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05012371-9023@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20271025
DTEND;VALUE=DATE:20271026
SUMMARY:Everolimus: Phase 2 readout est. (NCT05012371)
DESCRIPTION:Everolimus\, phase 2\, Renal Cell Carcinoma.\nStudy: Lenvatinib
  With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatme
 nt of Metastatic Renal Cell Cancer\nEstimated primary completion: 25 Octob
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/everolimus#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05012
 371
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05663710-1974@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT05663710)
DESCRIPTION:Nivolumab\, phase 1/2\, Renal Cell Carcinoma.\nStudy: Phase 1b/
 2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab 
 in Treatment naïve Patients With Advanced Clear Cell RCC\nEstimated prima
 ry completion: 30 October 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05663710
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05663710-2031@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Cabozantinib: Phase 1/2 readout est. (NCT05663710)
DESCRIPTION:Cabozantinib\, phase 1/2\, Clear Cell Renal Cell Carcinoma.\nSt
 udy: Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib 
 and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC\nE
 stimated primary completion: 30 October 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/cabozantinib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05663710
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227415-2009@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20271102
DTEND;VALUE=DATE:20271103
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT07227415)
DESCRIPTION:Ipilimumab\, phase 1/2\, Renal Cell Carcinoma.\nStudy: Symbioti
 c-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alon
 e and in Combination With Other Anticancer Therapies in Adults With Locall
 y Advanced or Metastatic Renal Cell Cancer\nEstimated primary completion: 
 2 November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipil
 imumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07227415
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227415-2214@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20271102
DTEND;VALUE=DATE:20271103
SUMMARY:Axitinib: Phase 1/2 readout est. (NCT07227415)
DESCRIPTION:Axitinib\, phase 1/2\, Renal Cell Carcinoma.\nStudy: Symbiotic-
 GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone 
 and in Combination With Other Anticancer Therapies in Adults With Locally 
 Advanced or Metastatic Renal Cell Cancer\nEstimated primary completion: 2 
 November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/axitin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7227415
URL:https://assetmemo.bio/drug/axitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227415-10820@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20271102
DTEND;VALUE=DATE:20271103
SUMMARY:Casdatifan: Phase 1/2 readout est. (NCT07227415)
DESCRIPTION:Casdatifan\, phase 1/2\, Clear Cell Renal Cell Carcinoma.\nStud
 y: Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404
  Dosed Alone and in Combination With Other Anticancer Therapies in Adults 
 With Locally Advanced or Metastatic Renal Cell Cancer\nEstimated primary c
 ompletion: 2 November 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/casdatifan#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07227415
URL:https://assetmemo.bio/drug/casdatifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07933419-2008@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20271115
DTEND;VALUE=DATE:20271116
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07933419)
DESCRIPTION:Bevacizumab\, phase 1/2\, Ovarian Cancer.\nStudy: Phase Ib/II C
 linical Study of QLS5133 Combination Therapy in Advanced Solid Tumors\nEst
 imated primary completion: 15 November 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07933419
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06730672-9023@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20271227
DTEND;VALUE=DATE:20271228
SUMMARY:Everolimus: Phase 2 readout est. (NCT06730672)
DESCRIPTION:Everolimus\, phase 2\, Renal Cell Carcinoma.\nStudy: An Explora
 tory Study on the Failure of Immunotherapy With Vorolanib Combined With Ev
 erolimus\nEstimated primary completion: 27 December 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/everolimus#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06730672
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07816770-2214@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Axitinib: Phase 2 readout est. (NCT07816770)
DESCRIPTION:Axitinib\, phase 2\, Renal Cell Carcinoma.\nStudy: MANTIS-RCC: 
 Toripalimab-Axitinib Induction in TLS-Positive Advanced Non-Clear Cell and
  Renal Medullary Carcinomas\nEstimated primary completion: 30 December 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/axitinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07816770
URL:https://assetmemo.bio/drug/axitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07744932-2214@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Axitinib: Phase 2 readout est. (NCT07744932)
DESCRIPTION:Axitinib\, phase 2\, Renal Cell Carcinoma.\nStudy: SABR Combine
 d With Axitinib and Toripalimab for Oligometastatic Renal Cell Carcinoma\n
 Estimated primary completion: 30 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/axitinib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07744932
URL:https://assetmemo.bio/drug/axitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06362369-1974@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT06362369)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed 
 by Nivolumab Monotherapy\nEstimated primary completion: 31 December 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06362369
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06362369-2009@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT06362369)
DESCRIPTION:Ipilimumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed
  by Nivolumab Monotherapy\nEstimated primary completion: 31 December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06362369
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07488533-2237@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0748853
 3)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Renal Cell Carcin
 oma.\nStudy: Comparing the Combination of Sullumab and Fruquintinib in Pos
 toperative Adjuvant Therapy for High Recurrence Risk Non Transparent Renal
  Cell Carcinoma\nEstimated primary completion: 31 December 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/fruquintinib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07488533
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07776717-2214@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Axitinib: Phase 2 readout est. (NCT07776717)
DESCRIPTION:Axitinib\, phase 2\, Renal Cell Carcinoma.\nStudy: TACTIC-RCC: 
 Toripalimab Plus Axitinib Induction With Selective Deferred Cytoreductive 
 Nephrectomy in TLS-Positive Advanced Clear Cell Renal Cell Carcinoma\nEsti
 mated primary completion: 31 December 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/axitinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07776717
URL:https://assetmemo.bio/drug/axitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05048212-1974@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05048212)
DESCRIPTION:Nivolumab\, phase 2\, Renal Cell Carcinoma.\nStudy: A Phase II 
 Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untre
 ated Renal Cell Carcinoma Brain Metastases\nEstimated primary completion: 
 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/niv
 olumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05048212
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06863311-1974@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06863311)
DESCRIPTION:Nivolumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Trial of Za
 nzalintinib (XL092) in Combination With Immunotherapy in Patients Who Prog
 ress on Adjuvant Therapy in Clear Cell RCC\nEstimated primary completion: 
 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/niv
 olumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06863311
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04981509-2008@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT04981509)
DESCRIPTION:Bevacizumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Testing o
 f Bevacizumab\, Erlotinib\, and Atezolizumab in Combination for Advanced-S
 tage Kidney Cancer\nEstimated primary completion: 31 December 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT04981509
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05048212-2009@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT05048212)
DESCRIPTION:Ipilimumab\, phase 2\, Renal Cell Carcinoma.\nStudy: A Phase II
  Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untr
 eated Renal Cell Carcinoma Brain Metastases\nEstimated primary completion:
  31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ip
 ilimumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05048212
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05048212-2031@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT05048212)
DESCRIPTION:Cabozantinib\, phase 2\, Renal Cell Carcinoma.\nStudy: A Phase 
 II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Un
 treated Renal Cell Carcinoma Brain Metastases\nEstimated primary completio
 n: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 cabozantinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05048212
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06863311-2819@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Zanzalintinib: Phase 2 readout est. (NCT06863311)
DESCRIPTION:Zanzalintinib\, phase 2\, Clear Cell Renal Cell Carcinoma.\nStu
 dy: Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Pa
 tients Who Progress on Adjuvant Therapy in Clear Cell RCC\nEstimated prima
 ry completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/zanzalintinib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06863311
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05738694-2214@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Axitinib: Phase 3 readout est. (NCT05738694)
DESCRIPTION:Axitinib\, phase 3\, Renal Cell Carcinoma.\nStudy: Neoadjuvant 
 of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Re
 nal Cell Carcinoma\nEstimated primary completion: 31 December 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/axitinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05738694
URL:https://assetmemo.bio/drug/axitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07593040-11244@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Welireg (Belzutifan): Phase 2 readout est. (NCT07593040)
DESCRIPTION:Welireg (Belzutifan)\, phase 2\, Renal Cell Carcinoma.\nStudy: 
 Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Rena
 l Cell Carcinoma\nEstimated primary completion: January 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/belzutifan#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07593040
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01217931-1918@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Votrient (Pazopanib): Phase 2 readout est. (NCT01217931)
DESCRIPTION:Votrient (Pazopanib)\, phase 2\, Renal Cell Carcinoma.\nStudy: 
 Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START
  Trial\nEstimated primary completion: 31 January 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/pazopanib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT01217931
URL:https://assetmemo.bio/drug/pazopanib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01217931-2008@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT01217931)
DESCRIPTION:Bevacizumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Sequentia
 l Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial\nE
 stimated primary completion: 31 January 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT01217931
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01217931-9023@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Everolimus: Phase 2 readout est. (NCT01217931)
DESCRIPTION:Everolimus\, phase 2\, Renal Cell Carcinoma.\nStudy: Sequential
  Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial\nEs
 timated primary completion: 31 January 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/everolimus#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT01217931
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05578664-1973@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05578664)
DESCRIPTION:Pembrolizumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Efficac
 y of PErioperative PEmbrolizumab Treatment in Patients With Resectable Met
 astases From Kidney Cancer\nEstimated primary completion: March 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05578664
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07630363-2214@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Axitinib: Phase 1/2 readout est. (NCT07630363)
DESCRIPTION:Axitinib\, phase 1/2\, Renal Cell Carcinoma.\nStudy: PTC-Guided
  Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC\nEstimated pri
 mary completion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/axitinib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07630363
URL:https://assetmemo.bio/drug/axitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03793166-2009@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Ipilimumab: Phase 3 readout est. (NCT03793166)
DESCRIPTION:Ipilimumab\, phase 3\, Renal Cell Carcinoma.\nStudy: Immunother
 apy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With 
 Cabozantinib for Patients With Advanced Kidney Cancer\, The PDIGREE Study\
 nEstimated primary completion: 1 March 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT03793166
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03793166-2031@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Cabozantinib: Phase 3 readout est. (NCT03793166)
DESCRIPTION:Cabozantinib\, phase 3\, Clear Cell Renal Cell Carcinoma.\nStud
 y: Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Ni
 volumab With Cabozantinib for Patients With Advanced Kidney Cancer\, The P
 DIGREE Study\nEstimated primary completion: 1 March 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/cabozantinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT03793166
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05269381-1973@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05269381)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrol
 izumab for Treatment of Advanced Solid Tumors\nEstimated primary completio
 n: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pem
 brolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05269381
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03682289-1959@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Durvalumab: Phase 2 readout est. (NCT03682289)
DESCRIPTION:Durvalumab\, phase 2\, Urothelial Carcinoma.\nStudy: Ceralasert
 ib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patie
 nts With Solid Tumors\nEstimated primary completion: 31 March 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT03682289
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07011719-10820@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Casdatifan: Phase 3 readout est. (NCT07011719)
DESCRIPTION:Casdatifan\, phase 3\, Clear Cell Renal Cell Carcinoma.\nStudy:
  Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in P
 atients With Advanced Clear Cell Renal Cell Carcinoma\nEstimated primary c
 ompletion: April 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/casdatifan#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07011719
URL:https://assetmemo.bio/drug/casdatifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07023432-11244@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280414
DTEND;VALUE=DATE:20280415
SUMMARY:Welireg (Belzutifan): Phase 2 readout est. (NCT07023432)
DESCRIPTION:Welireg (Belzutifan)\, phase 2\, Renal Cell Carcinoma.\nStudy: 
 Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmeta
 static Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)\nEstimated primary com
 pletion: 14 April 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/belzutifan#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07023432
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06794229-1974@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280606
DTEND;VALUE=DATE:20280607
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06794229)
DESCRIPTION:Nivolumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Neoadjuvant
  Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Ino
 perable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Met
 astasis\nEstimated primary completion: 6 June 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06794229
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06794229-2819@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280606
DTEND;VALUE=DATE:20280607
SUMMARY:Zanzalintinib: Phase 2 readout est. (NCT06794229)
DESCRIPTION:Zanzalintinib\, phase 2\, Clear Cell Renal Cell Carcinoma.\nStu
 dy: Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Adva
 nced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non
 -measurable Metastasis\nEstimated primary completion: 6 June 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/zanzalintinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06794229
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07578025-2819@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280624
DTEND;VALUE=DATE:20280625
SUMMARY:Zanzalintinib: Phase 2 readout est. (NCT07578025)
DESCRIPTION:Zanzalintinib\, phase 2\, Clear Cell Renal Cell Carcinoma.\nStu
 dy: Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Can
 cer After Progression on Immunotherapy\nEstimated primary completion: 24 J
 une 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zanzalintin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7578025
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04977453-2494@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:GI-101A: Phase 1/2 readout est. (NCT04977453)
DESCRIPTION:GI-101A\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: GI-10
 1/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvat
 inib in Advanced Solid Tumors\nEstimated primary completion: 30 June 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/gi-101a#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT04977453
URL:https://assetmemo.bio/drug/gi-101a#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06284564-1974@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06284564)
DESCRIPTION:Nivolumab\, phase 2\, Renal Cell Carcinoma.\nStudy: A Phase II 
 Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evol
 ocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOO
 ST-RCC)\nEstimated primary completion: 1 October 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06284564
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05086692-1973@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20281020
DTEND;VALUE=DATE:20281021
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05086692)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Beta-only IL-2 ImmunoTherapY Study\nEstimated primary completion: 20 Oc
 tober 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05086692
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07037004-1973@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20281024
DTEND;VALUE=DATE:20281025
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07037004)
DESCRIPTION:Pembrolizumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Adding 
 a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment 
 of Renal Cell Cancer After Surgery\nEstimated primary completion: 24 Octob
 er 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 037004
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07691476-1973@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07691476)
DESCRIPTION:Pembrolizumab\, phase 2\, Renal Cell Carcinoma.\nStudy: A Phase
  2 Multicenter Single-Arm Clinical Trial of Zanzalintinib and Pembrolizuma
 b in Subjects With Resectable Clear Cell Renal Cell Carcinoma\nEstimated p
 rimary completion: 31 October 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07691476
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07691476-2819@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Zanzalintinib: Phase 2 readout est. (NCT07691476)
DESCRIPTION:Zanzalintinib\, phase 2\, Clear Cell Renal Cell Carcinoma.\nStu
 dy: A Phase 2 Multicenter Single-Arm Clinical Trial of Zanzalintinib and P
 embrolizumab in Subjects With Resectable Clear Cell Renal Cell Carcinoma\n
 Estimated primary completion: 31 October 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/zanzalintinib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07691476
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05501054-1626@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Ciforadenant: Phase 1/2 readout est. (NCT05501054)
DESCRIPTION:Ciforadenant\, phase 1/2\, Renal Cell Carcinoma.\nStudy: Phase 
 1b/2 Trial of Ipilimumab\, Nivolumab\, and Ciforadenant (Adenosine A2a Rec
 eptor Antagonist) in First-line Advanced Renal Cell Carcinoma.\nEstimated 
 primary completion: 1 November 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/ciforadenant#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05501054
URL:https://assetmemo.bio/drug/ciforadenant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05501054-1974@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT05501054)
DESCRIPTION:Nivolumab\, phase 1/2\, Renal Cell Carcinoma.\nStudy: Phase 1b/
 2 Trial of Ipilimumab\, Nivolumab\, and Ciforadenant (Adenosine A2a Recept
 or Antagonist) in First-line Advanced Renal Cell Carcinoma.\nEstimated pri
 mary completion: 1 November 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05501054
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05501054-2009@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT05501054)
DESCRIPTION:Ipilimumab\, phase 1/2\, Renal Cell Carcinoma.\nStudy: Phase 1b
 /2 Trial of Ipilimumab\, Nivolumab\, and Ciforadenant (Adenosine A2a Recep
 tor Antagonist) in First-line Advanced Renal Cell Carcinoma.\nEstimated pr
 imary completion: 1 November 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05501054
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06053658-1974@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06053658)
DESCRIPTION:Nivolumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Phase 2 Stu
 dy of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal
  Cell Carcinoma\nEstimated primary completion: 1 November 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06053658
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06708949-1974@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20281215
DTEND;VALUE=DATE:20281216
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06708949)
DESCRIPTION:Nivolumab\, phase 2\, Renal Cell Carcinoma.\nStudy: A Randomize
 d Phase 2 Trial of Nivolumab\, Relatlimab Plus Ipilimumab vs. Nivolumab Pl
 us Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)\nEstimated
  primary completion: 15 December 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06708949
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06708949-2009@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20281215
DTEND;VALUE=DATE:20281216
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT06708949)
DESCRIPTION:Ipilimumab\, phase 2\, Renal Cell Carcinoma.\nStudy: A Randomiz
 ed Phase 2 Trial of Nivolumab\, Relatlimab Plus Ipilimumab vs. Nivolumab P
 lus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)\nEstimate
 d primary completion: 15 December 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06708949
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07165418-9023@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Everolimus: Phase 3 readout est. (NCT07165418)
DESCRIPTION:Everolimus\, phase 3\, Renal Cell Carcinoma.\nStudy: A Comparis
 on of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patie
 nts With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment
  With Immunotherapy Monotherapy or in Combination With TKI\nEstimated prim
 ary completion: 30 December 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/everolimus#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07165418
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07611825-2009@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07611825)
DESCRIPTION:Ipilimumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Gut Microb
 iota Modulation for Immunotherapy Resensitization in Advanced Renal Cell C
 arcinoma\nEstimated primary completion: 31 December 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07611825
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06004336-1973@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06004336)
DESCRIPTION:Pembrolizumab\, phase 2\, Renal Cell Carcinoma.\nStudy: A Rando
 mized Trial of Maintenance Systemic Therapy After Radiation for Oligometas
 tatic Renal Cell Carcinoma (ASTROs)\nEstimated primary completion: 1 Janua
 ry 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 004336
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07840001-1973@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07840001)
DESCRIPTION:Pembrolizumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Neoadju
 vant Belzutifan Plus Pembrolizumab in High-Risk\, Locally Advanced Clear C
 ell Renal Cell Carcinoma\nEstimated primary completion: April 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07840001
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07840001-11244@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Welireg (Belzutifan): Phase 2 readout est. (NCT07840001)
DESCRIPTION:Welireg (Belzutifan)\, phase 2\, Renal Cell Carcinoma.\nStudy: 
 Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk\, Locally Advanced 
 Clear Cell Renal Cell Carcinoma\nEstimated primary completion: April 2029.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/belzutifan#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07840001
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07877194-2009@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290412
DTEND;VALUE=DATE:20290413
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07877194)
DESCRIPTION:Ipilimumab\, phase 2\, Renal Cell Carcinoma.\nStudy: A Clinical
  Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab for Ad
 vanced Renal Cancer\nEstimated primary completion: 12 April 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07877194
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07043608-2819@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Zanzalintinib: Phase 2 readout est. (NCT07043608)
DESCRIPTION:Zanzalintinib\, phase 2\, Clear Cell Renal Cell Carcinoma.\nStu
 dy: Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone
  Metastases\nEstimated primary completion: 30 April 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/zanzalintinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07043608
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-1959@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Durvalumab: Phase 2 readout est. (NCT03228667)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: QUIL
 T-3.055: A Study of Combination Immunotherapies in Patients Who Have Previ
 ously Received Treatment With Immune Checkpoint Inhibitors\nEstimated prim
 ary completion: 31 August 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT03228667
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-1973@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03228667)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Q
 UILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Pr
 eviously Received Treatment With Immune Checkpoint Inhibitors\nEstimated p
 rimary completion: 31 August 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT03228667
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-1974@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03228667)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: QUILT
 -3.055: A Study of Combination Immunotherapies in Patients Who Have Previo
 usly Received Treatment With Immune Checkpoint Inhibitors\nEstimated prima
 ry completion: 31 August 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT03228667
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-2017@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Avelumab: Phase 2 readout est. (NCT03228667)
DESCRIPTION:Avelumab\, phase 2\, Merkel Cell Carcinoma.\nStudy: QUILT-3.055
 : A Study of Combination Immunotherapies in Patients Who Have Previously R
 eceived Treatment With Immune Checkpoint Inhibitors\nEstimated primary com
 pletion: 31 August 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/avelumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT03228667
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07576725-1974@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07576725)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Low D
 ose\, Reduced Frequency Nivolumab for the Treatment of Unresectable or Met
 astatic Cancer\, AFFORD IO Trial\nEstimated primary completion: 31 August 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07576725
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07469683-2214@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Axitinib: Phase 2 readout est. (NCT07469683)
DESCRIPTION:Axitinib\, phase 2\, Renal Cell Carcinoma.\nStudy: An Open-labe
 l\, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety 
 of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib M
 onotherapy as a Second-line Treatment for Locally Advanced or Metastatic C
 lear Cell Renal Cell Carcinoma\nEstimated primary completion: October 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/axitinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07469683
URL:https://assetmemo.bio/drug/axitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07293351-2009@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20291128
DTEND;VALUE=DATE:20291129
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT07293351)
DESCRIPTION:Ipilimumab\, phase 1/2\, Renal Cell Carcinoma.\nStudy: A Study 
 to Evaluate the Safety\, Tolerability\, and Efficacy of Pumitamig Alone or
  in Combination With Other Agents in Participants With Advanced Renal Cell
  Carcinoma (RCC) (ROSETTA RCC-208)\nEstimated primary completion: 28 Novem
 ber 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0729
 3351
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07293351-2031@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20291128
DTEND;VALUE=DATE:20291129
SUMMARY:Cabozantinib: Phase 1/2 readout est. (NCT07293351)
DESCRIPTION:Cabozantinib\, phase 1/2\, Renal Cell Carcinoma.\nStudy: A Stud
 y to Evaluate the Safety\, Tolerability\, and Efficacy of Pumitamig Alone 
 or in Combination With Other Agents in Participants With Advanced Renal Ce
 ll Carcinoma (RCC) (ROSETTA RCC-208)\nEstimated primary completion: 28 Nov
 ember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cabozanti
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07293351
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07277972-2214@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Axitinib: Phase 2 readout est. (NCT07277972)
DESCRIPTION:Axitinib\, phase 2\, Renal Cell Carcinoma.\nStudy: Iparomlimab 
 and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for 
 the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carc
 inoma That Has Failed First-Line Systemic Therapy\nEstimated primary compl
 etion: 30 November 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/axitinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07277972
URL:https://assetmemo.bio/drug/axitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07188896-2009@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07188896)
DESCRIPTION:Ipilimumab\, phase 2\, Renal Cell Carcinoma.\nStudy: A Randomiz
 ed Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Niv
 olumab in First-line Advanced Renal Cell Carcinoma (RCC)\nEstimated primar
 y completion: 30 November 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07188896
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06976021-1973@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06976021)
DESCRIPTION:Pembrolizumab\, phase 2\, Cervical Cancer.\nStudy: Immune PET a
 nd Proteomics for the Assessment of Response to Spatially Fractionated or 
 Palliative Radiotherapy With or Without Immunotherapy\nEstimated primary c
 ompletion: December 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06976021
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07715565-2009@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07715565)
DESCRIPTION:Ipilimumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Ipilimumab
  N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Adva
 nced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective\, M
 ulticenter\, Single-Arm\, Phase II Clinical Trial\nEstimated primary compl
 etion: December 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /ipilimumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07715565
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07620574-1974@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Nivolumab: Phase 3 readout est. (NCT07620574)
DESCRIPTION:Nivolumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: Long-Te
 rm Extension Study for Participants Previously Enrolled in an Exelixis-Spo
 nsored Study\nEstimated primary completion: 31 May 2030. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07620574
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07620574-2031@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Cabozantinib: Phase 3 readout est. (NCT07620574)
DESCRIPTION:Cabozantinib\, phase 3\, Hepatocellular Carcinoma.\nStudy: Long
 -Term Extension Study for Participants Previously Enrolled in an Exelixis-
 Sponsored Study\nEstimated primary completion: 31 May 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/cabozantinib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07620574
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07620574-2819@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Zanzalintinib: Phase 3 readout est. (NCT07620574)
DESCRIPTION:Zanzalintinib\, phase 3\, Colorectal Cancer.\nStudy: Long-Term 
 Extension Study for Participants Previously Enrolled in an Exelixis-Sponso
 red Study\nEstimated primary completion: 31 May 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/zanzalintinib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07620574
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07489495-2819@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20301127
DTEND;VALUE=DATE:20301128
SUMMARY:Zanzalintinib: Phase 3 readout est. (NCT07489495)
DESCRIPTION:Zanzalintinib\, phase 3\, Renal Cell Carcinoma.\nStudy: A Clini
 cal Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal C
 ell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)\nEstimated primary 
 completion: 27 November 2030. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/zanzalintinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07489495
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223424-1973@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07223424)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: P
 atient Preference for Subcutaneous vs. Intravenous Immune Therapy\nEstimat
 ed primary completion: 30 November 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07223424
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223424-1974@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07223424)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Patie
 nt Preference for Subcutaneous vs. Intravenous Immune Therapy\nEstimated p
 rimary completion: 30 November 2030. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07223424
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07239596-2008@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07239596)
DESCRIPTION:Bevacizumab\, phase 1/2\, Renal Cell Carcinoma.\nStudy: Phase I
 b/II Clinical Study of SHR-8068 Combined Anti-tumor Drugs in the Treatment
  of Advanced Renal Cell Carcinom\nEstimated primary completion: December 2
 030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07239596
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06146777-1973@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20301201
DTEND;VALUE=DATE:20301202
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06146777)
DESCRIPTION:Pembrolizumab\, phase 3\, Renal Cell Carcinoma.\nStudy: Multi-c
 lassifier System for Stratifying Stage III Papillary Renal Cell Carcinoma 
 of Receiving Adjuvant Therapy\nEstimated primary completion: 1 December 20
 30. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0614677
 7
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07904156-2237@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 3 readout est. (NCT0790415
 6)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 3\, Renal Cell Carcin
 oma.\nStudy: A Phase III Randomized Controlled Trial of Serplulimab Plus F
 ruquintinib as Adjuvant Therapy for High-Risk Non-Clear Cell Renal Cell Ca
 rcinoma\nEstimated primary completion: 30 December 2030. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/fruquintinib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07904156
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06866262-1974@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20310801
DTEND;VALUE=DATE:20310802
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT06866262)
DESCRIPTION:Nivolumab\, phase 1/2\, Renal Cell Carcinoma.\nStudy: Inulin Ge
 l in Combination With Ipilimumab and Nivolumab for the Treatment of Metast
 atic or Locally Advanced Kidney Cell Cancer\, ICON Trial\nEstimated primar
 y completion: 1 August 2031. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06866262
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06866262-2009@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20310801
DTEND;VALUE=DATE:20310802
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT06866262)
DESCRIPTION:Ipilimumab\, phase 1/2\, Renal Cell Carcinoma.\nStudy: Inulin G
 el in Combination With Ipilimumab and Nivolumab for the Treatment of Metas
 tatic or Locally Advanced Kidney Cell Cancer\, ICON Trial\nEstimated prima
 ry completion: 1 August 2031. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/ipilimumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06866262
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05155033-1973@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20310901
DTEND;VALUE=DATE:20310902
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05155033)
DESCRIPTION:Pembrolizumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Phase I
 I Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma a
 nd Renal Cell Carcinoma\nEstimated primary completion: 1 September 2031. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05155033
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05155033-5442@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20310901
DTEND;VALUE=DATE:20310902
SUMMARY:Proleukin (aldesleukin): Phase 2 readout est. (NCT05155033)
DESCRIPTION:Proleukin (aldesleukin)\, phase 2\, Renal Cell Carcinoma.\nStud
 y: Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic 
 Melanoma and Renal Cell Carcinoma\nEstimated primary completion: 1 Septemb
 er 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/aldesleukin#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0515
 5033
URL:https://assetmemo.bio/drug/aldesleukin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07049926-2819@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20311026
DTEND;VALUE=DATE:20311027
SUMMARY:Zanzalintinib: Phase 1/2 readout est. (NCT07049926)
DESCRIPTION:Zanzalintinib\, phase 1/2\, Renal Cell Carcinoma.\nStudy: Subst
 udy 03C: A Study of Combination Therapies in Participants With Renal Cell 
 Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-
 3475-03C/KEYMAKER-U03)\nEstimated primary completion: 26 October 2031. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/zanzalintinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07049926
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07049926-11244@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20311026
DTEND;VALUE=DATE:20311027
SUMMARY:Welireg (Belzutifan): Phase 1/2 readout est. (NCT07049926)
DESCRIPTION:Welireg (Belzutifan)\, phase 1/2\, Renal Cell Carcinoma.\nStudy
 : Substudy 03C: A Study of Combination Therapies in Participants With Rena
 l Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Thera
 py (MK-3475-03C/KEYMAKER-U03)\nEstimated primary completion: 26 October 20
 31. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/belzutifan#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07049926
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07689240-1973@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20320101
DTEND;VALUE=DATE:20320102
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07689240)
DESCRIPTION:Pembrolizumab\, phase 3\, Renal Cell Carcinoma.\nStudy: Testing
  the Investigational Medication Pembrolizumab After Kidney Removal for Pat
 ients With Non-Clear Cell Renal Cell Carcinoma\nEstimated primary completi
 on: 1 January 2032. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 embrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07689240
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227402-2819@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20320227
DTEND;VALUE=DATE:20320228
SUMMARY:Zanzalintinib: Phase 3 readout est. (NCT07227402)
DESCRIPTION:Zanzalintinib\, phase 3\, Renal Cell Carcinoma.\nStudy: A Clini
 cal Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney 
 Cancer Following Adjuvant Therapy (MK-6482-033)\nEstimated primary complet
 ion: 27 February 2032. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/zanzalintinib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07227402
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227402-11244@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20320227
DTEND;VALUE=DATE:20320228
SUMMARY:Welireg (Belzutifan): Phase 3 readout est. (NCT07227402)
DESCRIPTION:Welireg (Belzutifan)\, phase 3\, Renal Cell Carcinoma.\nStudy: 
 A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent 
 Kidney Cancer Following Adjuvant Therapy (MK-6482-033)\nEstimated primary 
 completion: 27 February 2032. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/belzutifan#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07227402
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04198766-1973@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20330731
DTEND;VALUE=DATE:20330801
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04198766)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytr
 uda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexav
 alent OX40 Agonist)\nEstimated primary completion: July 2033. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04198766
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07510334-1974@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20330801
DTEND;VALUE=DATE:20330802
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07510334)
DESCRIPTION:Nivolumab\, phase 2\, Renal Cell Carcinoma.\nStudy: VSV-IFNβ-N
 IS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastat
 ic Clear Cell Renal Cell Carcinoma\nEstimated primary completion: 1 August
  2033. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07510334
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07510334-2009@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20330801
DTEND;VALUE=DATE:20330802
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07510334)
DESCRIPTION:Ipilimumab\, phase 2\, Renal Cell Carcinoma.\nStudy: VSV-IFNβ-
 NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metasta
 tic Clear Cell Renal Cell Carcinoma\nEstimated primary completion: 1 Augus
 t 2033. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT075103
 34
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
